Clinical outcomes of combination treatment with FMS‐like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia
Year: 2026
Type: article
Source: British Journal of Haematology
DOI: 10.1111/bjh.70671
Authors: Catherine Gutierrez Moore, Donian I. Chyong, Naval Daver, Brandon J. Aubrey, Kayleigh R. Marx, Koichi Takahashi, Yasmin Abaza, Catherine C. Smith, Philip C. Amrein, Hanno Hock, Gabriela Hobbs, Rupa Narayan, Michelle H. Lee, Jenna A. Moran, Meghan Bergeron, Julia E. Foster, Alexander E. Perl, Mark J. Levis, Courtney D. DiNardo, Andrew M. Brunner, Amir T. Fathi
Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of California, San Francisco, University of Pennsylvania, Johns Hopkins University, Johns Hopkins Medicine
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Celgene, Actinium Pharmaceuticals, Jazz Pharmaceuticals, PTC Therapeutics, Agios Pharmaceuticals, Arog Pharmaceuticals, Incyte, Syndax Pharmaceuticals, Revolution Medicines, Bayer HealthCare, Astellas Pharma, Servier, National Institutes of Health, Genentech, Loxo Oncology, FUJIFILM Pharmaceuticals U.S.A., Daiichi Sankyo Europe
OpenAlex ID: W7168185482